Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

8.6K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
8.6K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

61
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serious mental illness and cancer: A call to action for equitable care.

CA: a cancer journal for clinicians·2026
Same author

Post-treatment circulating tumor DNA clinical features, prognosis in HPV-positive oropharynx cancer.

Oral oncology·2026
Same author

Targeted regeneration of post-radiation epithelium without promoting cancer recurrence.

Research square·2026
Same author

Feasibility of Immediate Dental Implantation During Scapular Free Flap Reconstruction of the Head and Neck.

Head & neck·2026
Same author

Preliminary insights into methylation patterns in Agent Orange exposed thyroid cancers: a pilot study.

Environmental pollution (Barking, Essex : 1987)·2025
Same author

Decision-making capacity evaluation in older cancer patients: A call to action.

Palliative & supportive care·2025

Related Experiment Video

Updated: Mar 13, 2026

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

1.1K

Neoadjuvant Therapy in Differentiated Thyroid Cancer.

Rajan P Dang1, Daniel McFarland2, Valerie H Le1

  • 1Department of Medical Education, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

International Journal of Surgical Oncology
|October 18, 2016
PubMed
Summary

Neoadjuvant chemotherapy and targeted therapies like lenvatinib show promise for treating advanced differentiated thyroid cancer (DTC). These treatments may improve surgical outcomes for patients with invasive DTC.

More Related Videos

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy
05:12

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy

Published on: May 12, 2023

5.2K
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.4K

Related Experiment Videos

Last Updated: Mar 13, 2026

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

1.1K
Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy
05:12

Transoral Endoscopic Thyroidectomy Vestibular Approach for Thyroid Lobectomy

Published on: May 12, 2023

5.2K
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.4K

Area of Science:

  • Oncology
  • Surgical Oncology

Background:

  • Differentiated thyroid cancer (DTC) invasion can necessitate extensive surgeries like laryngectomy.
  • Neoadjuvant therapy is being explored for advanced DTC cases.
  • Identifying effective neoadjuvant strategies is crucial for improving patient outcomes.

Purpose of the Study:

  • To evaluate the potential role of neoadjuvant therapy in managing advanced differentiated thyroid cancer.
  • To review existing evidence on neoadjuvant chemotherapy and targeted therapies for DTC.

Main Methods:

  • A review of three studies on neoadjuvant chemotherapy for DTC was conducted.
  • Literature search included studies from Slovenia and Japan.
  • Analysis of data from the SELECT trial and phase II Pazopanib data.

Main Results:

  • Neoadjuvant chemotherapy demonstrated good response rates in selected DTC cases.
  • Targeted therapy lenvatinib showed efficacy and rapid response in DTC treatment.
  • Pazopanib also exhibited promising results in phase II trials for DTC.

Conclusions:

  • Neoadjuvant chemotherapy may be beneficial for advanced DTC management.
  • Tyrosine kinase inhibitors (TKIs) show potential as neoadjuvant treatments for DTC.
  • Further research into neoadjuvant TKIs could enhance surgical resection and patient care.